About: Ursodeoxycholic acid for cystic fibrosis-related liver disease

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ursodeoxycholic acid for cystic fibrosis-related liver disease Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2017 (fr) наукова стаття, опублікована у вересні 2017 (uk) im September 2017 veröffentlichter wissenschaftlicher Artikel (de)
publication date	wds:Q57126201-87C60328-D23B-4EB8-8957-A8CFB8DD42FE
publication date	2017-09-11 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57126201-F4C430D8-32E2-410C-96BD-53F7E1E990AB
language of work or name	English
cites work	wds:Q57126201-09BFE9E4-475F-4038-870A-2E2833A9E894 wds:Q57126201-1633F4FF-B4C1-45BF-AFF7-5C0F78B950ED wds:Q57126201-2CFE1352-9C49-44F9-A2CC-8A5ABA11EBE7 wds:Q57126201-2D72957C-CCA0-4896-AEEF-FDA7A4C2F9B1 wds:Q57126201-2EE87EFC-674B-497C-A7F7-1972D3799C44 wds:Q57126201-44A58B74-B789-491B-96F2-636DE018BE0A wds:Q57126201-4625F223-A319-4D3D-9975-097338CEF5B6 wds:Q57126201-492B0F04-9893-4264-BCBD-BB9070CCC9F2 wds:Q57126201-5E63CF38-B280-4E27-B00B-103C5B803439 wds:Q57126201-7578E188-CECB-43C1-B920-4DC0B1C74769 wds:Q57126201-82C7AF0F-9C86-47BF-A4AC-52EEF528DDC4 wds:Q57126201-9CC9B406-525C-4AB3-8817-2715D0701E48 wds:Q57126201-A42034A6-4227-450B-8C16-9E44577B1EDF wds:Q57126201-ABE33F87-78E9-44A2-BE9E-6CB6556FB3B9 wds:Q57126201-B21DAD87-B3E0-499C-ACAA-70ECD9ECC700 wds:Q57126201-C7B6B8B0-85C0-4D7F-8542-31F65BC69858 wds:Q57126201-C9393F0B-0588-487F-A0E1-DC2A2C1FF9DC wds:Q57126201-CCDF256D-A13B-4AD4-8ABD-2771F53D6B88 wds:Q57126201-CF778CC1-FA90-44BA-A473-76A56B4064A1 wds:Q57126201-D6640BA9-149F-431D-8AA7-AFC1E3BFCC55 wds:Q57126201-E00995DD-341D-445C-A075-7CC33174A5B0 wds:Q57126201-F7FD9DCC-C52E-4EFF-8FC5-614C7E28E48D
cites work	Effect of a Medium Dose of Ursodeoxycholic Acid with or without Taurine Supplementation on the Nutritional Status of Patients with Cystic Fibrosis Ursodeoxycholic acid improves the hepatic metabolism of essential fatty acids and retinol in children with cystic fibrosis Meta-analyses involving cross-over trials: methodological issues Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up Ursodeoxycholic acid for cystic fibrosis-related liver disease. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood The role of hepatobiliary scintigraphy in cystic fibrosis. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease. Liver disease in cystic fibrosis Ursodeoxycholic acid for cystic fibrosis-related liver disease Ursodeoxycholic acid for cystic fibrosis-related liver disease Liver disease in cystic fibrosis: an update Abdominal radiology in cystic fibrosis. Liver and biliary problems in cystic fibrosis Ursodeoxycholic acid in cystic fibrosis-related liver disease: a systematic review
author name string	wds:Q57126201-47F870EC-DA4E-4C91-8FBB-CD6AC9B90A38 wds:Q57126201-EC077CBD-53CA-4C18-BEBD-58FE22F403F5
author name string	Katharine Cheng Rosalind L Smyth
rdfs:label	Ursodeoxycholic acid for cystic fibrosis-related liver disease (en) Ursodeoxycholic acid for cystic fibrosis-related liver disease (nl)
skos:prefLabel	Ursodeoxycholic acid for cystic fibrosis-related liver disease (en) Ursodeoxycholic acid for cystic fibrosis-related liver disease (nl)
name	Ursodeoxycholic acid for cystic fibrosis-related liver disease (en) Ursodeoxycholic acid for cystic fibrosis-related liver disease (nl)
author	wds:Q57126201-D9480AA5-06A6-4D41-96CA-5B3E269A16FE
author	Deborah Ashby
title	wds:Q57126201-672FF6E1-0066-4D15-A4D7-319D90E88279
title	Ursodeoxycholic acid for cystic fibrosis-related liver disease (en)
page(s)	wds:Q57126201-50D5CC98-CC17-464C-B37C-325931F2D547
page(s)	CD000222
instance of	wds:Q57126201-40173b8a-26ec-46ee-978c-85ba1d9182d3 wds:Q57126201-5FA5FAFF-6094-4150-B719-ED697668B45F
instance of	meta-analysis scholarly article
main subject	wds:Q57126201-AC5BDC45-E81A-454B-AE0E-03D73504A96C
main subject	liver disease
PubMed ID	wds:Q57126201-2FBA8BB0-B594-4D54-AD7F-CA5AC55060CF
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28891588
PubMed ID	28891588
published in	wds:Q57126201-C4A22A09-1735-4450-B435-142FD74A590F
published in	Cochrane Database of Systematic Reviews
volume	wds:Q57126201-9724B98F-9C1A-461C-9372-04935C89B287
volume	9
DOI	wds:Q57126201-FB0C52B9-CE46-4B83-8CD2-DBD84FC1E2ED
DOI	http://dx.doi.org/10.1002/14651858.CD000222.PUB4
DOI	10.1002/14651858.CD000222.PUB4
is owl:sameAs of	Ursodeoxycholic acid for cystic fibrosis-related liver disease
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57126201
is cites work of	The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients Liver disease in patients with cystic fibrosis. Animal models for cystic fibrosis liver disease (CFLD) Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases Hepatic Manifestations of Cystic Fibrosis Increased prescribing of ursodeoxycholic acid in Norway Multidisciplinary Care for Cystic Fibrosis Liver Disease: Where Does the Adult Hepatologist Fit In?
is cites work of	wds:Q91919553-99F81257-4B98-422F-BDC9-DAE35E62A8BA wds:Q50042663-930BF164-0161-4AE1-A88B-9A49B2711A2A wds:Q57113804-A995E454-14F1-4854-8B41-442F9009FDE3 wds:Q92532305-4F6D47F6-7239-4F58-BF25-41A23FC83FDB

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 196 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software